ICON Public (NASDAQ:ICLR) Sets New 52-Week Low – Should You Sell?

ICON Public Limited (NASDAQ:ICLR) shares hit a new 52-week low on Monday . The stock traded as low as $168.00 and last traded at $170.77, with a volume of 543736 shares trading hands. The stock had previously closed at $179.07.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ICLR shares. Robert W. Baird dropped their target price on ICON Public from $221.00 to $203.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. JPMorgan Chase & Co. decreased their target price on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $263.00 price target on shares of ICON Public in a research report on Wednesday, January 15th. William Blair reiterated an “outperform” rating on shares of ICON Public in a report on Tuesday, January 14th. Finally, Barclays cut their target price on ICON Public from $275.00 to $240.00 and set an “overweight” rating on the stock in a research report on Friday, February 21st. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ICON Public presently has an average rating of “Moderate Buy” and a consensus target price of $272.50.

ICON Public Price Performance

The stock has a market capitalization of $14.06 billion, a P/E ratio of 18.22, a PEG ratio of 1.86 and a beta of 1.21. The company has a 50 day moving average of $190.43 and a 200-day moving average of $221.63. The company has a quick ratio of 1.34, a current ratio of 1.26 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.41 by $0.01. The business had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. Sell-side analysts predict that ICON Public Limited will post 13.38 EPS for the current year.

Institutional Trading of ICON Public

Several hedge funds have recently bought and sold shares of ICLR. Foyston Gordon & Payne Inc boosted its position in shares of ICON Public by 27.3% during the fourth quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company’s stock worth $10,845,000 after buying an additional 11,089 shares during the period. Captrust Financial Advisors grew its stake in shares of ICON Public by 2.0% in the fourth quarter. Captrust Financial Advisors now owns 35,301 shares of the medical research company’s stock worth $7,403,000 after purchasing an additional 701 shares in the last quarter. State of Tennessee Department of Treasury increased its holdings in shares of ICON Public by 1.0% during the fourth quarter. State of Tennessee Department of Treasury now owns 158,947 shares of the medical research company’s stock valued at $33,333,000 after purchasing an additional 1,600 shares during the period. Motley Fool Wealth Management LLC grew its position in ICON Public by 2.3% in the 4th quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company’s stock valued at $13,342,000 after buying an additional 1,466 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its position in ICON Public by 128.2% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 1,166 shares of the medical research company’s stock valued at $245,000 after buying an additional 655 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.